0 224

Cited 0 times in

Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis

DC Field Value Language
dc.contributor.author김창곤-
dc.contributor.author김현기-
dc.contributor.author김효송-
dc.contributor.author라선영-
dc.contributor.author이충근-
dc.contributor.author정민규-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.date.accessioned2023-06-02T01:02:11Z-
dc.date.available2023-06-02T01:02:11Z-
dc.date.issued2022-02-
dc.identifier.issn0732-183X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194609-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAmerican Society of Clinical Oncology-
dc.relation.isPartOfJOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleMulticenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorChang Gon Kim-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorChoong-kun Lee-
dc.contributor.googleauthorHei-Cheul Jeung-
dc.contributor.googleauthorDong-Hoe Koo-
dc.contributor.googleauthorWoo Kyun Bae-
dc.contributor.googleauthorDae Young Zang-
dc.contributor.googleauthorHyunki Kim-
dc.contributor.googleauthorHyun Cheol Cheol Chung-
dc.identifier.doi10.1200/JCO.2022.40.4_suppl.330-
dc.contributor.localIdA05991-
dc.contributor.localIdA01108-
dc.contributor.localIdA01202-
dc.contributor.localIdA01316-
dc.contributor.localIdA03259-
dc.contributor.localIdA03606-
dc.contributor.localIdA03773-
dc.contributor.localIdA03794-
dc.relation.journalcodeJ01331-
dc.identifier.eissn1527-7755-
dc.identifier.urlhttps://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.330-
dc.contributor.alternativeNameKim, Chang Gon-
dc.contributor.affiliatedAuthor김창곤-
dc.contributor.affiliatedAuthor김현기-
dc.contributor.affiliatedAuthor김효송-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor이충근-
dc.contributor.affiliatedAuthor정민규-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor정희철-
dc.citation.volume40-
dc.citation.number4 suppl-
dc.citation.startPage330-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL ONCOLOGY, Vol.40(4 suppl) : 330, 2022-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.